• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Genetic liability to rheumatoid arthritis in relation to coronary artery disease and stroke risk
ConclusionThis study found that genetic liability to RA was associated with increased risk of CAD and intracerebral hemorrhage and that the association for CAD might be mediated by CRP. The heightened cardiovascular risk should be actively monitored and managed in RA patients, and this may include damping systemic inflammation.
Source: Arthritis and Rheumatology - May 18, 2022 Category: Rheumatology Authors: Shuai Yuan, Paul Carter, Amy M. Mason, Fangkun Yang, Stephen Burgess, Susanna C. Larsson Tags: Full Length Source Type: research

Anti –Citrullinated Protein Antibody Specificities, Rheumatoid Factor Isotypes, and Incident Cardiovascular Events in Patients With Rheumatoid Arthritis
ConclusionRF isotypes and ACPAs are associated with future CV events in patients with RA. ACPA levels and number of subspecificities seem more important than the occurrence of particular subspecificities, and these associations were not explained by a history of ever smoking.
Source: Arthritis and Rheumatology - September 6, 2020 Category: Rheumatology Authors: Helga Westerlind, Johan R önnelid, Monika Hansson, Lars Alfredsson, Linda Mathsson‐Alm, Guy Serre, Martin Cornillet, Rikard Holmdahl, Per‐Johan Jakobsson, Karl Skriner, Lars Klareskog, Saedis Saevarsdottir, Johan Askling Tags: Original Article Source Type: research

Biologics May Prevent Cardiovascular Events in Rheumatoid Arthritis by Inhibiting Coronary Plaque Formation and Stabilizing High ‐Risk Lesions
ConclusionOur findings indicate that in RA, biologic DMARD use is associated with reduced CVD risk, protective calcification of noncalcified lesions, and lower likelihood of new plaque formation in patients with early atherosclerosis.
Source: Arthritis and Rheumatology - August 6, 2020 Category: Rheumatology Authors: George A. Karpouzas, Sarah R. Ormseth, Elizabeth Hernandez, Matthew J. Budoff Tags: Original Article Source Type: research

Anti ‐citrullinated protein antibody specificities, rheumatoid factor isotypes and incident cardiovascular events in patients with rheumatoid arthritis
ConclusionsRF isotypes and ACPA are associated with future CV events. ACPA levels and number of sub ‐specificities seem more important than the occurrence of particular sub‐specificities. These associations were not explained by smoking.
Source: Arthritis and Rheumatology - May 30, 2020 Category: Rheumatology Authors: Helga Westerlind, Johan R önnelid, Monika Hansson, Lars Alfredsson, Linda Mathsson‐Alm, Guy Serre, Martin Cornillet, Rikard Holmdahl, Per‐Johan Jakobsson, Karl Skriner, Lars Klareskog, Saedis Saevarsdottir, Johan Askling Tags: FULL LENGTH Source Type: research

Biologics may prevent cardiovascular events in rheumatoid arthritis by inhibiting coronary plaque formation and stabilizing high ‐risk lesions
ConclusionIn rheumatoid arthritis, bDMARD use associated with reduced CVD risk, protective calcification of non ‐calcified lesions and lower likelihood of new plaque formation in patients with early atherosclerosis.
Source: Arthritis and Rheumatology - April 20, 2020 Category: Rheumatology Authors: George A Karpouzas, Sarah R Ormseth, Elizabeth Hernandez, Matthew J Budoff Tags: FULL LENGTH Source Type: research

A Multicenter, Randomized, Placebo ‐Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis
ConclusionAtorvastatin 40 mg daily is safe and results in a significantly greater reduction of LDL cholesterol level than placebo in patients with RA. The 34% CVE risk reduction is consistent with the Cholesterol Treatment Trialists ’ Collaboration meta‐analysis of statin effects in other populations.
Source: Arthritis and Rheumatology - July 21, 2019 Category: Rheumatology Authors: George D. Kitas, Peter Nightingale, Jane Armitage, Naveed Sattar, Jill J. F. Belch, Deborah P. M. Symmons, on behalf of the TRACE RA Consortium, George Kitas, Jill Belch, Deborah Symmons, Hawys Williams, Shobna Vasishta, Rebecca Storey, Pete Tags: Original Article Source Type: research

Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long ‐Term Extension Studies of Tofacitinib in Patients with Rheumatoid Arthritis
ConclusionIn this post ‐hoc analysis, after 24 weeks of tofacitinib, increased HDL‐c, but not increases in LDL‐c or TC, appeared to be associated with lower future MACE risk. Further data are needed to test the cardiovascular safety of tofacitinib.This article is protected by copyright. All rights reserved.
Source: Arthritis and Rheumatology - April 16, 2019 Category: Rheumatology Authors: Christina Charles ‐Schoeman, Ryan DeMasi, Hernan Valdez, Koshika Soma, Lie‐Ju Hwang, Mary G. Boy, Pinaki Biswas, Iain B. McInnes Tags: Full Length Source Type: research

Trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis (TRACE RA): A multicenter, randomized, placebo controlled trial
ConclusionAtorvastatin 40mg daily was safe and resulted in significantly greater reduction of LDLc than placebo in patients with RA. The 40% (adjusted) CVE risk reduction is consistent with the Cholesterol Treatment Trialists ’ Collaboration meta‐analysis of statin effects in other populations.This article is protected by copyright. All rights reserved.
Source: Arthritis and Rheumatology - April 14, 2019 Category: Rheumatology Authors: George D. Kitas, Peter Nightingale, Jane Armitage, Naveed Sattar, Jill J.F. Belch, Deborah P.M. Symmons, The TRACE RA consortium, George Kitas, Jill Belch, Deborah Symmons, Hawys Williams, Shobna Vasishta, Rebecca Storey, Peter Nightingale, Tags: Full Length Source Type: research

Ibudilast Inhibits Chemokine Expression in Rheumatoid Arthritis Synovial Fibroblasts and Exhibits Immunomodulatory Activity in Experimental Arthritis
ConclusionOur findings indicate that ibudilast reduces the expression and/or secretion of inflammatory mediators from activated human leukocytes and RASFs, inhibits Th17 cell responses in vivo, and improves established arthritis. Given the established safety profile of ibudilast in humans, its clinical evaluation in RA, either alone or in combination with a TNF inhibitor, should be considered.
Source: Arthritis and Rheumatology - April 11, 2019 Category: Rheumatology Authors: Felix I. L. Clanchy, Richard O. Williams Tags: Original Article Source Type: research

Ibudilast inhibits chemokine expression in rheumatoid synovial fibroblasts and exhibits immunomodulatory activity in experimental arthritis
ConclusionIbudilast reduced the expression and/or secretion of inflammatory mediators from activated human leukocytes and RASF, inhibited Th17 responses in vivo and improved established arthritis. Given the established safety profile of ibudilast in man, its clinical evaluation in RA, either alone or in combination with a TNF inhibitor, should be considered.This article is protected by copyright. All rights reserved.
Source: Arthritis and Rheumatology - November 26, 2018 Category: Rheumatology Authors: Felix I.L. Clanchy, Richard O. Williams Tags: Full Length Source Type: research